SCHEMBL7254231

SCHEMBL7254231

c1csc(Nc2nccs2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
TDP1 Q9NUW8 3/20 0.47
NPC1 O15118 5/20 0.44
RAB9A P51151 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
KDM4E B2RXH2 2/20 0.44
PLA2G7 Q13093 1/20 0.44
GRM4 Q14833 1/20 0.44
PKM P14618 2/20 0.43
ATM Q13315 1/20 0.43
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 1/20 0.41
LMNA P02545 4/20 0.41
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 2/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1369210 0.78 ALDH1A1 (0.50) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL1553690 0.75 ALDH1A1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
Pyridine SCHEMBL28371825 0.75 ALDH1A1 (0.46) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL717594 0.75 GAA (0.42) ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL722560 0.73 RAB9A (0.59) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL17397927 0.73 PLA2G7 (0.49) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL2546678 0.72 GRM4 (0.47) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
SCHEMBL8906815 0.72 PLA2G7 (0.59) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
Hydrochloric Acid SCHEMBL6833454 0.72 RAB9A (0.57) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2
Bromide SCHEMBL7502411 0.72 RAB9A (0.57) ALDH1A1TDP1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6562840-B1 Non-peptidic inhibitors of proteolytic enzymes such as urokinase 3-DIMENSIONAL PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-6403633-B2 USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS 3-DIMENSIONAL PHARMACEUTICALS, INC. 2002-06-11 US disclosed
EP-1150979-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2001-11-07 EP disclosed
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors ILLIG CARL R (US) 2001-10-18 US disclosed
US-6291514-B1 Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000047578-A1 HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031781-A1 Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors SERPINE1, PRSS3, PRSS2 ALDH1A1 3209/4885TDP1 1010/4885NPC1 2579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.